Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Verona Pharma ( (VRNA) ) has provided an update.
On September 24, 2025, Verona Pharma‘s shareholders approved the acquisition by Merck & Co., Inc. through its subsidiary, Vol Holdings LLC, for $107 per American Depository Share, totaling approximately $10 billion. The transaction, structured as a scheme of arrangement under English law, awaits the High Court of Justice’s sanction, with the effective date expected to be October 7, 2025, pending certain closing conditions. This acquisition marks a significant step for Verona Pharma, potentially enhancing its market position and operational capabilities in the biopharmaceutical industry.
The most recent analyst rating on (VRNA) stock is a Hold with a $107.00 price target. To see the full list of analyst forecasts on Verona Pharma stock, see the VRNA Stock Forecast page.
Spark’s Take on VRNA Stock
According to Spark, TipRanks’ AI Analyst, VRNA is a Neutral.
Verona Pharma’s stock is bolstered by strong revenue growth and a successful product launch, contributing to positive momentum. However, profitability challenges, high valuations, and potential overbought conditions temper enthusiasm. The company’s improved financial flexibility is a key strength, though ongoing operating losses and high SG&A expenses are notable risks.
To see Spark’s full report on VRNA stock, click here.
More about Verona Pharma
Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs.
Average Trading Volume: 3,501,777
Technical Sentiment Signal: Buy
Current Market Cap: $9.15B
For an in-depth examination of VRNA stock, go to TipRanks’ Overview page.